| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CapsoVision, Inc.
$6.55
-0.1 (-1.5%)
Market Cap
348.00 M
EPS
-0.56
P/E Ratio
-
Value Trade
607.15 K
6.97 %
Week
13.38 %
1 Month
-12.18 %
3 Month
-7.52 %
6 Month
32.8 %
5 Year
32.8 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
181.64 K
52 Week Range
4.38 - 15.37
% held by Insiders
45.92 %
% held by Institutions
9.56 %
Enterprise Value
342.64 M
Total Shares
53.21 M
Short %
6.6 %
Float Shares
28.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CapsoVision, Inc.
5Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲Management ChangeCorporate
Subscribe to view catalyst details
TBD
◆Product LaunchPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
No drug pipeline
CapsoVision, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CV▼ -1.5%today
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision, Inc. announced that its AI Highlights tool for the CapsoCam Plus system received FDA clearance on September 25, 2026. This AI-assisted reading tool is designed to help physicians review small bowel capsule endoscopy studies more efficiently by highlighting suspected abnormal lesions. The tool integrates with CapsoView and CapsoCloud, enhancing workflows for healthcare professionals.
Read more →CVCapsoVision to Participate in Upcoming Investor Conferences
CapsoVision, Inc. will participate in two upcoming investor conferences, including the H.C. Wainwright 28th Annual Global Investment Conference and the 5th Annual ROTH Healthcare Opportunities Conference. The company will present on-demand and hold one-on-one meetings with investors. CapsoVision focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases.
Read more →CVCapsoVision Reports Second Quarter 2026 Financial Results
CapsoVision, Inc. reported a 10% revenue increase for Q2 2026, totaling $3.6 million. The company launched its AI Highlights™ feature internationally and anticipates FDA clearance by Q3 2026. Despite revenue growth, gross margins fell due to competitive pressures and increased operating expenses. The company continues to expand its product pipeline and customer base.
Read more →CVCapsoVision® Announces International Launch of AI Highlights
CapsoVision, Inc. has announced the international launch of AI Highlights, a feature for its CapsoCam Plus system designed to enhance the review process of small bowel capsule endoscopy studies. This AI-enabled tool identifies frames with clinically relevant findings, supporting physicians in their assessments. While the product is available in markets like the EU, it has not yet received FDA clearance for use in the U.S.
Read more →CVCapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
CapsoVision, a medical technology company, will announce its second quarter 2026 financial results on August 13, 2026. Following the release, a conference call will be held to discuss the results and provide a corporate update. The company specializes in advanced imaging and AI-enabled capsule endoscopy solutions.
Read more →CV▼ -9.2%on this news· ran to -22% by day 1
CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
CapsoVision, Inc. has appointed Dr. David S. Shields to its Board of Directors, effective July 1, 2026. Dr. Shields, a board-certified gastroenterologist with over 40 years of experience, succeeds Dr. Joanne C. Imperial, who will continue as a clinical consultant. The company is poised for growth with upcoming product launches and advancements in AI-enabled capsule endoscopy technology.
Read more →CVCapsoVision Reports First Quarter 2026 Financial Results
CapsoVision, Inc. reported its first quarter 2026 financial results, maintaining revenue at $2.8 million. The company noted increased clinical use of its CapsoCam Plus product and secured key customer renewals. However, gross profit decreased by 11%, and operating expenses rose due to ongoing development efforts. The anticipated FDA clearance for its AI-assisted reading feature is expected mid-year.
Read more →CV▲ +10.6%on this news
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
CapsoVision, Inc. will announce its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will follow the results release, allowing for investor engagement. The company focuses on advanced imaging and AI solutions for gastrointestinal diagnostics, with notable products in its pipeline.
Read more →CVCapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
CapsoVision, Inc. reported its financial results for Q4 and full year 2025, showing a 15% increase in revenue driven by higher sales of CapsoCam Plus capsules. The company made significant strides in AI technology and submitted an AI module for FDA approval. However, operating expenses rose due to development initiatives, impacting profitability.
Read more →CV▲ +11.2%on this news· ran to +34% by day 3
CapsoVision Announces $14 Million Private Placement Financing
CapsoVision, Inc. has successfully closed a $14 million private placement to accredited investors, selling 2,867,089 shares at a 5% discount. The funds will be used for corporate purposes, including R&D and marketing. The company also announced preliminary financial results for 2025, with revenues of $3.9 million in Q4 and $13.6 million for the full year.
Read more →CVCapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
CapsoVision, Inc. will announce its fourth quarter and full year 2025 financial results on March 26, 2026. A conference call will follow the release to discuss the results and provide updates. The company focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases, with products like CapsoCam Plus® and the upcoming CapsoCam Colon™.
Read more →CV▼ -11%on this news· ran to -21% by day 3
CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus Company Preparing to Commence Commercialization Following U.S. FDA 510(k) Clearance
CapsoVision, Inc. has announced the submission of its 510(k) application to the FDA for an AI-assisted reading module to enhance its CapsoCam Plus capsule endoscopy system. This development aims to improve the detection of significant pathologies and decrease clinician review time. Following FDA clearance, CapsoVision plans to initiate commercialization efforts. The company positions itself as a leader in the capsule endoscopy space with its integrated imaging and AI technology.
Read more →CVCapsoVision Reports Third Quarter 2025 Financial Results
CapsoVision, Inc. reported third quarter 2025 financial results with revenues of $3.5 million, representing a 19% increase from the prior year. The company welcomed significant growth in new accounts and a substantial user base for its CapsoCam Plus product. Additionally, it submitted an application for Breakthrough Device Designation to expedite the development of an endoscopy capsule aimed at early-stage pancreatic cancer detection. Despite increases in operating expenses and a modest decline in gross margin, CapsoVision highlighted its commitment to advancing healthcare technology through strategic partnerships and innovations.
Read more →CVCapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma -
CapsoVision has submitted an application to the FDA seeking Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system aimed at early-stage pancreatic cancer detection. This innovative device offers a non-invasive method for screening a disease known for its high mortality rate due to late-stage diagnosis. The Breakthrough Devices Program could expedite its development and regulatory review process. However, the company faces potential hurdles, including meeting FDA eligibility requirements for the designation and obtaining marketing authorization.
Read more →CVCapsoVision Appoints David Garcia as Senior Vice President of Finance Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growth
CapsoVision, a medical technology company, has appointed David Garcia as Senior Vice President of Finance, effective November 3, 2025. Garcia brings over 20 years of financial leadership experience, including roles at Matterport, Inc., where he played a key part in the company's IPO. His expertise is expected to support CapsoVision's growth strategy and development pipeline, particularly in advanced imaging and AI-enabled capsule endoscopy solutions. The company aims to transform the detection of gastrointestinal diseases through innovative technology.
Read more →CVCapsoVision Reports Second Quarter 2025 Financial Results
CapsoVision, Inc. reported a 17% rise in revenue for Q2 2025, totaling $3.3 million, alongside a 75% growth in new accounts. The company also completed a successful IPO, raising approximately $23.4 million to support expansion into new indications. While management remains optimistic about future growth through additional product enhancements and regulatory approvals, the financial report highlighted a $4.6 million operating loss and a significant decline in cash reserves, raising concerns about sustainability.
Read more →CVCapsoVision Announces Pricing of Initial Public Offering
CapsoVision, a commercial-stage medical technology company, has announced the pricing of its initial public offering (IPO) at $5.00 per share, totaling approximately $27.5 million in gross proceeds. Trading on the Nasdaq Capital Market is set to begin on July 2, 2025, under the ticker symbol CV. The company aims to utilize the funds to advance its innovative imaging technologies and expand its product pipeline targeting gastrointestinal diseases. The offering remains contingent upon standard closing conditions.
Read more →Competitive Position
How CV ranks across every disease it competes inCompetitive Position is a premium feature
See how CV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial